EPS (TTM) and P/E are suppressed: a stock split falls inside the trailing-four-quarter window, and SEC facts keep only the latest-filed value, so the as-filed quarterly EPS prints mix pre- and post-split bases — no single-basis trailing EPS exists to sum.
full derived coverage requires a plan
Output of a disclosed model — assumptions may be wrong. Research, not investment advice. See the Disclaimer.
— Months · distinct values (the real sample size).
Metric
Today
Own median
Own range
%ile
z
Sector med.
mo · distinct
P/E
—
P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
−256.4%
−91.4%
no band (54 mo · 5 distinct)
—
—
−36.9%
54 · 5
−439.0% (2024-02)
—
no band (24 mo · 2 distinct)
—
—
−15.4%
24 · 2
−7179.6% (2024-02)
—
no band (36 mo · 3 distinct)
—
—
−21.3%
36 · 3
−75.3%
−36.9%
no band (38 mo · 37 distinct)
—
—
5.1%
38 · 37
EPS Growth 3Y
—
P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
Sales Growth 3Y
—
no reconstructed observations for this name and metric.
Market Cap
$8.87M
not reconstructed — market cap was removed from the historical pass (never a ranking factor, and a reconstructed share count carries look-ahead risk). The single stored value is the forward-captured snapshot, not a series.
ROE (point-in-time)Health Care median, same monthshaded = own p10–p90 · dashed = own median · right-edge tick = today
shown for reference only — the reconstructed distribution did not clear the band gate, so no rank is quoted.
Multiple-implied price ladder · Full
Filed earnings only.
no P/E ladder — P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
Ladder not drawn for this name — the reason is above.ⓘ
Not a forecast: each row re-prices today's filed earnings at a multiple this company itself once traded at. It abstains rather than guess on a loss year or a broken per-share basis.
Every month uses only what was filed by then, split-adjusted. Delisted names are absent and a trough year can throw one huge reading, so read the median, not the edges.
Percentile through time (point-in-time cohort)
Loading the monthly cohort placement…
▸Comp setname your own peers — pick a pool or add tickers
IMNN is not drawn here: its newest pool year (CY2022) differs from the industry’s (CY2025), so its 0.0% is a different year’s share.
Growth, restated as sharewhere each pace has to END UP, by 2027
Its own realised pace— No growth rate was supplied to restate.
The pace the price requires— The growth today's price requires (our reverse-DCF) is a Pro metric — the realized-pace runway above is free.
IMNN share over time3 published years
Calendar year
2020
2021
2022
Share of covered pool
0.0%
0.0%
0.0%
year: this company's newest published… · share_5y: this company has no 2017… · coverage: 326 of the 351 members that…
Share of covered industry revenue · n=358 in Pharmaceuticals & Biotechnology · CY2022 pool · built 2026-08-19 not market shareⓘ
Covered filers only, not market share — private and uncovered companies are missing, so every share here reads high. Years are FX-converted and published only once most of the pool has filed.
